Products for Out-Licensing

Products Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at BD@nalpharma.com to know more about NAL’s products and partnering opportunities.

Respiratory and Allergy
 
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL6013 Levocetirizine ODF
505(b)(2) NDA
NAL6328 Tulobuterol 24-Hour Patch
505(b)(2) NDA
NAL6329 Formoterol 24-Hour Patch
505(b)(2) NDA
NAL6336 Montelukast ODF
505(b)(2) NDA
Top